Cue Biopharma Inc Dossier
Qualitative Analysis
Business overview
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics engineered to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary core engine is the Immuno-STAT® (Selective Targeting and Alteration of T cells) platform. This platform acts as artificial antigen-presenting cells, delivering a primary disease-specific antigen signal and a secondary co-modulatory signal to either activate or suppress targeted T cells without causing systemic toxicity. Cue Biopharma has recently undergone a strategic pivot, shifting its primary focus from oncology toward autoimmune and inflammatory diseases. Its lead autoimmune candidate is CUE-401, a preclinical bifunctional TGF-β/IL-2 fusion protein designed to promote immune tolerance by inducing and expanding regulatory T cells (Tregs). Additionally, the company is developing CUE-221, a novel anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Cue Biopharma executed a strategic reboot under newly appointed CEO Dr. Shao-Lee Lin, shifting its primary focus from oncology toward allergic and autoimmune diseases. This transformation is anchored by the licensing of CUE-221 (a late-stage anti-IgE antibody) and the clinical advancement of CUE-401.
Expected impact: Establishes Cue as a clinical-stage immunology company with a diversified pipeline targeting functional cures for allergic and autoimmune disorders.
To maximize the value of its proprietary Immuno-STAT platform while managing capital constraints, Cue Biopharma actively out-licenses its oncology and specific autoimmune assets to strategic partners (such as Boehringer Ingelheim and ImmunoScape) to secure non-dilutive funding and milestone payments.
Expected impact: Provides non-dilutive capital (such as the $7.5 million milestone from Boehringer Ingelheim in May 2026) and validates the therapeutic potential of the platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to CUE-221 (formerly Ascendant-221), a late-stage Phase 2 anti-IgE antibody with a dual-mechanism of action targeting allergic diseases.
Terms: $15 million upfront payment, with potential regulatory and commercial milestones of up to $676.5 million plus royalties.
Collaborating to develop and commercialize CUE-501, a differentiated B-cell depletion therapy for autoimmune diseases, leveraging Cue's Immuno-STAT platform.
Terms: $12 million upfront payment, research support, a $7.5 million preclinical milestone achieved in May 2026, and up to $337.5 million in potential future milestones plus royalties.
Advancing a novel in vivo approach to cell therapy for solid tumors by combining Cue's CUE-100 series of T-cell engagers with ImmunoScape's proprietary TCRs, allowing Cue to focus resources on its autoimmune programs.
Terms: Potential of up to ~$345 million in milestones plus royalties, and a 40% equity stake in ImmunoScape for Cue.